



Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

**Instructions:** Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

			URGENT		
MEMBER INFORMATION					
LAST NAME:		FIRST NAME:			
PHONE NUMBER:		DATE OF BIRTH:			
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:			
PATIENT INSURANCE ID NUI	MBER:				
MALE FEMALE HEIC	IBER, YOU WILL NEED TO SUBMIT A PHI DISCL	OSURE AUTHORIZATION FORM WITH THIS REC	QUEST WHICH CAN BE FOUND AT THE		
PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE):					
AUTHORIZED REPRESENTATIV	VE'S PHONE NUMBER:				
PRESCRIBER INFORMATION					
LAST NAME:		FIRST NAME:			
PRESCRIBER SPECIALTY:		EMAIL ADDRESS:			
NPI NUMBER:		DEA NUMBER:			
PHONE NUMBER:		FAX NUMBER:			
STREET ADDRESS:					
CITY:		STATE: ZIP CODE:			
REQUESTOR (if different than prescriber):		OFFICE CONTACT PERSON:			
MEDICATION OR MEDICAL	DISPENSING INFORMATION				
MEDICATION NAME:					
DOSE/STRENGTH:	FREQUENCY:	LENGTH OF THERAPY/REFILLS:	QUANTITY:		
□ NEW THERAPY       □ RENEWAL       IF RENEWAL: DATE THERAPY INITIATED:         DURATION OF THERAPY (SPECIFIC DATES):					

Continued on next page.







Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME:	MEMBER'S FIRST NAME:		
1. HAS THE PATIENT TRIED ANY OTHER	R MEDICATIONS FOR THIS CONDITION?	YES (if yes, complete below) NC	
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE):	<b>DURATION OF THERAPY</b> (SPECIFY DATES):	RESPONSE/REASON FOR FAILURE/ALLERGY:	
2. LIST DIAGNOSES:	0	ICD-10:	
<ul><li>□ Pulmonary arterial hypertension (PAH</li><li>□ Raynaud's phenomenon</li></ul>	1)		
□ Diagnosis:	ICD-10 Code(s):		
	N: PLEASE PROVIDE ALL RELEVANT CLIN	ICAL INFORMATION TO SUPPORT A	
Requests for branded Revatio susper	nsion:		
	eric sildenafil suspension AND Liqrev su	uspension? 🗆 Yes 🗆 No Please submit	
documentation.	Group 1 pulmonary arterial hypertens	•	
☐ Congenital heart disease (e.g., atria	ıl-septal defect)		
☐ Associated with surgical repair of a ventricular septal defect, patent duct	congenital systemic-to-pulmonary shu tus arteriosus)	unt of at least 1year in duration(e.g.,	
treatment)  □ HIV infection □ Idiopathic/primary PAH □ Portal hypertension □ Schistosomiasis	ive to acute vasoreactivity testing (AVT) cleroderma, systemic sclerosis, CREST sease)		
Does the patient have WHO function *Please provide documentation.	al class II, III, or IV?* □ Yes □ No		
Is patient's diagnosis confirmed by conformed by conformed by conformed by confirmed by confirme	ardiac catheterization? 🗆 Yes 🗆 N	o □ Yes □ No Please submit	
-	ed by cardiac catheterization a mean puth to confirm PAH?   Yes   No *Pleas		

© 2017–2023 by Magellan Rx Management All Rights Reserved. CAT0007

Revision Date: 5/1/24









Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

Does patient have, (at rest), measured by cardiac catheterization a pulmonary capillary wedge pressure (PCWP)
15mmHg or less via right heart cath to confirm PAH? ☐ Yes ☐ No *Please provide documentation.
Does patient have, (at rest), measured by cardiac catheterization a pulmonary vascular resistance (PVR) value
equaling 3 wood units or greater via right heart cath to confirm PAH?   Yes   No *Please provide documentation.
If patient has idiopathic PAH, hereditary PAH (excludes congenital heart disease like atrial=septal defect) or
drug/toxin induced PAH, did patient have had an acute vasoreactivity test? ☐ Yes ☐ No *Please provide
documentation.
Has patient been previously treated with a Calcium channel blocker? ☐ Yes ☐ No *Please provide documentation.
Select the prescribing physician's specialty:
□ Cardiology □ Nephrology
□ Pulmonology
□ Rheumatology
Does patient have a history of left-sided heart disease? ☐ Yes ☐ No ☐ Yes ☐ No Please submit documentation.
Does patient have severe renal insufficiency? ☐ Yes ☐ No ☐ Yes ☐ No Please submit documentation.
Does patient have pulmonary hypertension related to conditions other than previously specified?   No
For Raynaud's phenomenon, answer the following:
Is the prescribing physician a rheumatologist? ☐ Yes ☐ No
Is the patient's Raynaud's phenomenon secondary to systemic sclerosis/scleroderma?* ☐ Yes ☐ No
*Please provide documentation.
Has the patient received prior treatment with, and is intolerant of or resistant to, at least one calcium channel
blocker?*
*Please provide documentation.
Will the patient be using a calcium channel blocker on alternate days with Adcirca? ☐ Yes ☐ No
Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?
Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required
information is received.

© 2017–2023 by Magellan Rx Management All Rights Reserved. Revision Date: 5/1/24 CAT0007

Page 3 of 4







Caterpillar Prescription Drug Benefit Phone: 877-228-7909 Fax: 800-424-7640

**ATTESTATION:** I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification:

Date

**CONFIDENTIALITY NOTICE:** The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in re liance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

**FAX THIS FORM TO: 800-424-7640** 

MAIL REQUESTS TO: Magellan Rx Management Prior Authorization Program

Attn: CP – 4201 P.O. Box 64811 St. Paul, MN 55164-0811

 $\ \ \,$   $\ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \ \,$   $\ \,$   $\ \ \,$   $\ \, \,$   $\ \,$   $\ \,$   $\ \,$   $\ \,$   $\ \,$   $\ \,$   $\ \,$   $\ \,$ 

Page 4 of 4

